Loading stock data…
Mirum Pharmaceuticals (MIRM)
$113.03-1.33 (-1.16%)
Market ClosedLast close Jul 24
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Mirum Pharmaceuticals, Inc. in the Healthcare sector is trading at $113.03 with a market capitalization of $6.2B. Wall Street consensus targets $146.50 (14 analysts), implying a +29.6% move over the next 12 months. The stock is currently 13% below its 52-week high of $130.00, remaining 23.4% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +29.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $159.88M↑ | $148.93M↑ | $133.01M↑ | $127.78M↑ | $111.58M |
| Gross Profit | $131.08M↑ | $120.67M↑ | $107.47M↑ | $104.36M↑ | $88.57M |
| Operating Income | -$63.16M↓ | -$4.57M↓ | $2.60M↑ | -$4.99M↑ | -$10.18M |
| Net Income | -$790.15M↓ | -$5.73M↓ | $2.90M↑ | -$5.86M↑ | -$14.68M |
Peer Comparison
JNJUNHPFE
Fundamentals
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.21B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-329.43%
Volume
Today's trading volume
492,205
Recent News
Stocks To Watch: 14 Names Test And Tease New Buy Zones
A barrage of stocks to watch like Eli Lilly and Deere, show promise, alongside reminders to keep risk management in mind.
The Bull Case For Mirum Pharmaceuticals (MIRM) Could Change Following Priority FDA Review Of FOP Drug Zilurgisertib
Mirum Pharmaceuticals recently reported positive pivotal phase II results from the PROGRESS study of zilurgisertib in fibrodysplasia ossificans progressiva and received US FDA priority review acceptance for its new drug application, with a decision scheduled for late September 2026. This combination of encouraging data in an ultra-rare indication and accelerated regulatory review highlights Mirum’s potential to broaden its rare disease portfolio beyond its existing commercial assets. We’ll...
Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?
Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Is Mirum Pharmaceuticals, Inc. (MIRM) Emerging as a Rare Disease Growth Story After New FOP Data?
We recently compiled a list of the 10 Best Healthcare Stocks to Buy According to Wall Street Analysts. Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) is among the best healthcare stocks. TheFly reported on June 15 that Citizens reiterated its positive stance on MIRM, increasing its price objective to $146 from $140. The firm pointed to the growing potential […]
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.